Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
10x Genomics reported modest revenue growth but sharply improved profitability for 2025. Revenue was $166.0 million in Q4 2025, up 1% year over year, with full-year revenue of $642.8 million, a 5% increase from 2024. Excluding $44.1 million of non-recurring patent litigation settlement revenue, full-year revenue was $598.7 million, a 2% decline.
Q4 gross margin improved to 68% and full-year gross margin to 69%. Operating expenses fell 18% in Q4 and 17% for the year, helped by lower legal and personnel costs and a $49.9 million litigation settlement gain. Net loss narrowed to $16.3 million in Q4 2025 from $49.0 million a year earlier, and to $43.5 million for 2025 from $182.6 million in 2024.
The company ended 2025 with $523.4 million in cash, cash equivalents and marketable securities. For 2026, 10x Genomics guides to revenue of $600–$625 million, which represents 0% to 4% growth versus 2025 after excluding non-recurring patent-related revenue.
10x Genomics, Inc. filed a report stating that it has issued a press release with preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. The press release, dated January 11, 2026 and attached as Exhibit 99.1, covers key financial information for that quarter and the full year. The company notes that this information is being furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other documents.
10x Genomics, Inc. filed a report stating that it has issued a press release with preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. The press release, dated January 11, 2026 and attached as Exhibit 99.1, covers key financial information for that quarter and the full year. The company notes that this information is being furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other documents.
10x Genomics, Inc. filed a report stating that it has issued a press release with preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. The press release, dated January 11, 2026 and attached as Exhibit 99.1, covers key financial information for that quarter and the full year. The company notes that this information is being furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other documents.
FMR LLC and Abigail P. Johnson report beneficial ownership of 12,696,254.11 shares of 10x Genomics, Inc. Class A common stock, representing 10.8% of that class as of December 31, 2025. FMR has sole voting power over 12,658,759 shares and sole dispositive power over 12,696,254.11 shares, with no shared voting or dispositive power.
The reported amount includes 892,772 shares of Class B common stock held by investment companies advised by FMR subsidiaries, which are convertible into Class A shares on a 1:1 basis and represent 8.8579% of the outstanding Class B stock. The filing states that, assuming conversion of all outstanding Class B into Class A, the reported holding would represent 10.0324% of the Class A common stock. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of 10x Genomics.
10x Genomics, Inc. reported that Chief Executive Officer and director Serge Saxonov exercised stock options on January 5, 2026 to acquire 50,000 shares of Class A common stock at $1.20 per share. These shares now form part of his directly held stake of 1,071,556 Class A shares following the transaction.
The filing shows two option exercises, covering 17,463 and 32,537 underlying shares, from fully vested options expiring on October 18, 2027, leaving 173,600 stock options outstanding. In addition to his direct holdings, Saxonov is reported as trustee for three trusts that hold 27, 213,250 and 58,000 Class A shares, respectively.
10x Genomics, Inc. (TXG) reported an insider stock transaction by its Chief Financial Officer. On 11/24/2025, the CFO disposed of 11,888 shares of Class A common stock in a sale transaction at a price of $18.9983 per share. After this transaction, the officer beneficially owns 297,385 shares of Class A common stock in direct ownership form.
The company notes that the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, meaning the transaction was connected to equity compensation rather than an open-market liquidation of a larger personal position.
10x Genomics, Inc. reported an insider stock transaction by a senior executive. On 11/24/2025, a reporting person who serves as both a director and as President and Chief Scientific Officer sold 8,283 shares of Class A common stock of 10x Genomics, Inc. (TXG) at a price of $18.9983 per share. According to the explanation provided, the shares were sold to cover tax withholding obligations that arose when restricted stock units vested, meaning the transaction was tied to equity compensation rather than a discretionary open-market sale.
After this transaction, the reporting person beneficially owned 432,605 shares of Class A common stock in direct form. The Form 4 was filed for a single reporting person and does not report any derivative securities activity.
10x Genomics, Inc. (TXG) Chief Executive Officer and Director Serge Saxonov reported a sale of Class A common stock in a Form 4 filing. On 11/24/2025, he sold 13,261 shares at an average price of $18.9983 per share in a transaction coded "S," which the notes explain was to cover tax withholding obligations from vesting restricted stock units.
After this transaction, Saxonov beneficially owns 1,021,556 Class A shares directly. He also reports indirect ownership of 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, where he serves as trustee.
10x Genomics (TXG) announced a planned legal leadership transition. Eric S. Whitaker will retire as Chief Legal Officer effective January 1, 2026, after more than eight years with the company. He will remain an employee with reduced compensation and serve as Strategic Counsel, continuing to advise on ongoing legal matters.
Dr. Randy Wu, currently Vice President of Intellectual Property and Litigation, has been appointed General Counsel and Secretary effective January 1, 2026. Wu joined the company in August 2016 following his tenure at Orrick, Herrington & Sutcliffe LLP, and holds a Ph.D. in Biophysics (UCSF) and a J.D. (Stanford). CEO Serge Saxonov highlighted Whitaker’s leadership through key milestones, and emphasized continuity with Wu’s internal promotion.
10x Genomics (TXG) reported Q3 2025 results with revenue of $149.0 million and a net loss of $27.5 million. Gross margin was 67%. Products and services revenue fell 2% year over year as instruments declined 37% to $12.0 million, while consumables rose 1% to $127.9 million and services grew 29% to $8.1 million.
Year-to-date, revenue reached $476.8 million, including $45.8 million of license and royalty revenue tied to settlements with Vizgen and Bruker, alongside a $49.9 million gain on settlement. Cash, cash equivalents, and marketable securities totaled $482.1 million as of September 30, 2025.
The company closed the Scale Biosciences asset acquisition with $9.2 million cash and $13.5 million in stock (1,099,992 shares), recorded $22.4 million of contingent consideration at fair value, and expects a $20.0 million payment in Q1 2026. A May 2025 restructuring recorded $6.0 million in charges. Management noted revenues are expected to moderately increase sequentially in Q4 2025 and gross margin may fluctuate with mix and non-recurring items.
10x Genomics (TXG) furnished an 8-K announcing quarterly results. The company reported that it issued a press release with financial results for the quarter ended September 30, 2025, and attached it as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.
10x Genomics’ Class A common stock trades on Nasdaq under the symbol TXG. The exhibit list includes the press release dated November 6, 2025 and the Inline XBRL cover page file.